TBL12
Phase 2Small molecule
TBL12 is one of 10 small molecule programs targeting Asymptomatic Myeloma. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Asymptomatic Myeloma
#DrugCompanyPhaseTrials
1Arava
SanofiApproved
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Decadron
AAspen Global Incorporated
Approved
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Darzalex
Johnson & JohnsonPhase 3
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 2
Elranatamab
PfizerPhase 2
Tecentriq
RochePhase 1
Keytruda
Merck & Co.Phase 1
TBL12
NNYU Langone Health
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TBL12. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNYU Langone Health